Total
turnover in the half year was £14,119 million, up 28% at AER,
25% at CER, reflecting strong performance in all three product
groups. Commercial Operations turnover, excluding pandemic sales,
grew 15% at AER, 12% at CER. Specialty Medicines included
£1,773 million sales of Xevudy, which contributed 13 percentage
points of growth at AER and CER. Vaccines growth reflected strong
Shingrix performance
assisted by demand recovery and channel inventory build in the US,
partially offset by pandemic adjuvant
sales in H1 2021. General Medicines reflected the
post-pandemic recovery of the antibiotics market and the strong
performance of Trelegy in
respiratory across all regions.
Specialty Medicines
Specialty
Medicines sales were £5,839 million, up 69% at AER, 63% at
CER, driven by consistent growth in all therapy areas. Specialty
Medicines excluding sales of Xevudy, were £4,066 million, up
18% at AER, 14% at CER.
HIV
HIV
sales were £2,585 million with growth of 14% at AER,10% at
CER. The performance benefited from strong patient demand for the
new HIV medicines (Dovato,
Cabenuva, Juluca, Rukobia, and Apretude). Unfavourable international
tender phasing was broadly offset by favourable US channel
inventory movements.
New HIV
medicines delivered for the first-time half year sales of over one
billion pounds to £1,017 million, up 72% at AER, 66% at CER,
representing 39% of the total HIV portfolio compared to 26% in H1
2021. Sales of the oral two drug regimens Dovato and Juluca were £577 million and
£285 million, respectively, with combined growth of 51% at
AER, 47% at CER. Cabenuva,
the first long-acting injectable for the treatment of HIV-1
infection, recorded sales of £110 million. Apretude, the first long-acting
injectable for the
prevention of HIV-1 delivered sales of £10
million.
Oncology
Oncology
sales were £281 million, up 23% at AER, 19% at CER.
Zejula sales of £218
million were up 17% at AER, 14% at CER with diagnosis and treatment
rates continuing to be impacted by the pandemic especially in the
US. Sales of Blenrep of
£55 million increased 31% at AER, 26% at CER, reflecting
ongoing launches and growth in launched markets.
Immuno-inflammation,
Respiratory and Other
Immuno-inflammation,
Respiratory and Other sales were £1,200 million up 26% at AER,
21% at CER. Benlysta sales
were £512 million, up 31% at AER, 24% at CER, representing
strong underlying demand worldwide. Nucala sales were £662 million, up
21% at AER, 18% at CER, including US sales of £413 million up
24% at AER, 16% at CER. The performance reflected continued strong
patient demand and the launch of several additional
indications.
Pandemic
Sales
of Xevudy were £1,773
million, compared to £16 million sales in the first half of
last year. Sales were delivered in all regions; £793 million
in the US, £434 million in Europe, and £546 million in
International.
Vaccines
Vaccines
turnover was £3,384 million, up 21% at AER, 17% at CER.
Excluding unrepeated 2021 pandemic adjuvant sales, vaccine sales
increased 33% at AER, 30% at CER. The performance reflected a
favourable comparator to H1 2021, which was impacted by
COVID-19 related disruptions in
several markets, and the strong commercial execution of
Shingrix, particularly in
the US and Europe.
Meningitis
Meningitis
vaccines sales grew 8% at AER, 6% at CER to £447 million
mainly driven by Bexsero
(10% at AER, 9% at CER to £328 million) resulting from higher
CDC purchasing and increased share in the US, partially offset by
phasing of tenders in Europe.
Shingles
Shingrix sales more than doubled to £1,429 million
primarily due to demand recovery, strong commercial execution aimed
at shifting the shingles vaccination season forward and
earlier-than-expected channel inventory build in the US, and higher
demand in Germany. All regions grew significantly in H1 2022, with
41% of the growth contributed from outside of the US. Shingrix is now available in 23
countries.
Established Vaccines
Established
Vaccines grew 1% AER but decreased 1% at CER to £1,458 million
mainly as a result of lower International tender demand and
unfavourable phasing for Synflorix, lower sales for Cervarix, and MMR/V vaccines in
International, and the negative impact of a CDC stockpile borrow
for Rotarix. This decrease
was partially offset by higher demand for hepatitis vaccines and
Boostrix in the US and
Europe.
General Medicines
General
Medicines sales in the half year were £4,896 million, up 3% at
AER, 2% at CER, with the impact of generic competition in US,
Europe and Japan offset by Trelegy growth in respiratory and the
post-pandemic rebound of the antibiotic market since H2 2021, in
Other General Medicines.
Respiratory
Respiratory
sales were £3,184 million, up 6% at AER, 3% at CER. The
performance was driven by Trelegy sales of £807 million, up
50% AER, 43% CER, including strong growth across all regions. The
performance also benefitted from prior period RAR adjustments in
the US. Advair/Seretide
sales of £564 million decreased 19% at AER, 20% at CER
predominately reflecting the adverse impact of generic competition;
growth in certain International markets due to targeted promotion
offset the decrease.
Other General
Medicines
Other
General Medicines sales were £1,712 million, and decreased 1%
at AER, stable at CER. Augmentin sales were £259 million,
up 42% at AER, 48% at CER, reflecting the post pandemic rebound of
the antibiotic market since Q3 2021 in the International and Europe
regions. This offsets the ongoing adverse impact of generic
competition and approximately two percentage points impact from the
divestment of cephalosporin products in Q4 2021.
By
Region
US
In the
US, sales were £6,903 million, up 38% at AER, 29% at CER,
including Xevudy sales of
£793 million contributing ten percentage points of
growth.
In
Specialty Medicines, HIV sales were £1,591 million up 21% at
AER, 13% at CER driven by strong patient demand from all new HIV
products with sales of £662 million up 73% at AER, 62% at CER,
and favourable channel inventory movements. HIV medicines,
Dovato delivered sales of
£309 million and Cabenuva £95 million. Nucala in respiratory and Benlysta in immunology both continued
to grow double-digit and reflected ongoing and strong patient
demand. Oncology sales increased 14% at AER, 7% at CER with
diagnosis and treatment rates continuing to be impacted by the
pandemic.
Vaccine
sales were £1,789 million, up 38% at AER, 29% at CER.
Excluding the impact of COVID-19 vaccine adjuvant sales during the
first half of 2021, sales increased 64% at AER, 53% at CER. The
performance was primarily driven by Shingrix and reflected demand recovery
and the benefit of a favourable comparator in the first half of
2021 when sales were impacted by COVID-19 related disruptions.
Meningitis, Hepatitis, Infanrix/Pediarix, and Boostrix sales all grew reflecting CDC
purchasing patterns and demand recovery.
General
Medicines sales were £1,744 million up 9% at AER, 2% at CER,
driven by strong respiratory sales of Trelegy, which increased 57% at AER,
47% at CER, and reflected increased patient demand and growth of
the single inhaler triple therapy market.
Europe
In
Europe, sales were £3,209 million, up 27% at AER, 30% at CER,
including Xevudy sales of
£434 million contributing 17 percentage points of
growth.
In
Specialty Medicines, HIV sales were £635 million up 10% at
AER, 13% at CER primarily driven by strong patient demand from two
drug regimens Dovato and Juluca.
Dovato delivered sales of £216 million and Juluca £63 million. Benlysta in immunology, Nucala in respiratory, and several
Oncology medicines continued to show strong double-digit
growth.
Vaccine
sales were £823 million, up 36% at AER, 40% at CER. The
performance was driven by Shingrix sales of £311 million,
>100% at AER, >100% at CER, particularly in
Germany.
General
Medicines sales were £1,025 million and decreased 5% at AER,
3% at CER, reflecting the ongoing and adverse impact of generic
competitive pressures on Seretide. This was partly offset,
however, by strong demand for Trelegy in respiratory and the growth
of Augmentin following the
post-pandemic rebound of the antibiotic market since H2
2021.
International
International
sales were £4,007 million, up 16% at AER, 17% at CER,
including Xevudy sales of
£546 million contributing 14 percentage points of
growth.
In
Specialty Medicines, HIV sales were £359 million and decreased
4% at AER, 5% at CER, primarily driven by tender phasing; strong
Dovato growth partially
offset the performance. Combined Tivicay and Triumeq sales were £278 million
decreasing 14% at AER, 15% at CER. Nucala in respiratory and Benlysta in immunology both continued
to grow strongly reflecting biologic market growth in Japan and
addition to China’s National Reimbursement Drug
List.
Vaccine
sales were £772 million and decreased 13% at AER, 14% at CER.
Vaccine sales excluding the impact of COVID-19 vaccine adjuvant
sales in H1 2021 decreased 8% at AER, 9% at CER, primarily
reflecting the phasing of public tenders and the lower sales of
divested brands.
General
Medicines sales were £2,127 million up 4% at AER, 5% at CER.
Respiratory sales of £935 million increased 4% at AER, 5% at
CER reflecting strong growth of Trelegy, particularly in Japan, China,
and Canada. This performance, however, was offset by the adverse
impact of generic competition and a lower allergy season in Japan.
Other General Medicines sales of £1,192 million increased 4%
at AER, 5% at CER, and reflected growth of Augmentin following the post-pandemic
rebound of the antibiotic market since H2 2021.
|